spacer
home > pmps > autumn 2008 > the future’s bright
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future’s Bright

How do you think your sector has developed over the past 10 years?

Temperature controlled packaging has become a defined sector in the last 10 years, driven by the increasing use of biological products in the healthcare sector, such as erythropoietins for the treatment of anaemia and beta interferons for multiple sclerosis, anti-inflammatories and cancer treatments. These largely protein-based products are highly sensitive to temperature, requiring careful storage and distribution in order to be effective. The range from +2 to +8°C is such a prevalent specification that it has become a de facto standard. Other temperature requirements have since emerged, most notably temperate (+15 to +25 or +30°C). Regulatory awareness, notably that of the US FDA and the UK’s MHRA, and industry practice in the form of GxPs have kept pace with these demands, as has an array of shipping technologies, both passive and active.

What would you perceive as the biggest challenges facing the industry over the next 10 years?

The challenge now is to harmonise standards across an increasingly global platform. Industrial and international cooperation...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Tim Jennings is a Director of the French company Emball’iso SA and of two of its international affiliates. He has 10 years’ experience in the shipping of temperature sensitive products at two of the leading European companies in the field. Prior to these commercial roles Tim worked in the supply of engineering design and consultancy services to the pharmaceutical and petrochemical industries, specialising in ion exchange and adsorbent processes. Tim has a BSc (Hons) in Materials Technology.
spacer
Tim Jennings
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HPAPI 2020 conference to discuss containment solutions and ADC developments

On the 11th – 12th May 2020, industry professionals will convene in London to discuss the challenges of the HPAPI industry at the Highly Potent Active Pharmaceutical Ingredients conference. The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment - more often in the form of antibody drug conjugates (ADC).
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

INTERPHEX 2020

28-30 April 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement